JinQuan Wang

Dr. JinQuan Wang

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
KLKe Lin
Ke Lin
ZZZi-Zhuo Zhao
Zi-Zhuo Zhao
HBHua-Ben Bo
Hua-Ben Bo
XHXiaojuan Hao
Xiaojuan Hao
JWJinQuan Wang
JinQuan Wang
Ruthenium complexes are a new generation of metal antitumor drugs that are currently of great interest in multidisciplinary research. In this review article, we introduce the applications of ruthenium complexes in the diagnosis and therapy of tumors. We focus on the actions of ruthenium complexes on DNA, mitochondria, and endoplasmic reticulum of cells, as well as signaling pathways that induce tumor cell apoptosis, autophagy, and inhibition of angiogenesis. Furthermore, we highlight the use of ruthenium complexes as specific tumor cell probes to dynamically monitor the active biological component of the microenvironment and as excellent photosensitizer, catalyst, and bioimaging agents for phototherapies that significantly enhance the diagnosis and therapeutic effect on tumors. Finally, the combinational use of ruthenium complexes with existing clinical antitumor drugs to synergistically treat tumors is discussed.

1 September 2021 in Biomaterials
Verified
Journal Article
Closed access
FWFangmian Wei
Fangmian Wei
SKShi Kuang
Shi Kuang
TRThomas W. Rees
Thomas W. Rees
XLXinxing Liao
Xinxing Liao
JLJiangping Liu
Jiangping Liu
HCHui Chao
Hui Chao

1 May 2018 in Cancer Letters
Verified
Journal Article
Closed access
ZZZizhuo Zhao
Zizhuo Zhao
JWJiayi Wu
Jiayi Wu
XLXiaodi Liu
Xiaodi Liu
MLMing Liang
Ming Liang
XZXinchuan Zhou
Xinchuan Zhou
BLBaoming Luo
Baoming Luo

18 February 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KLKe Lin
Ke Lin
YRYi Rong
Yi Rong
DCDan Chen
Dan Chen
ZZZizhuo Zhao
Zizhuo Zhao
HBHuaben Bo
Huaben Bo
JWJinQuan Wang
JinQuan Wang
Combinational use of drugs has been a common strategy in cancer treatment because of synergistic advantages in reducing dose and toxicity, minimizing or delaying drug resistance. To improve the efficacy of chemotherapy, various potential combinations have been investigated. Ruthenium complex is considered a potential alternative of the platinum-based drugs due to its significant efficacy and safety. Previously, we reported that ruthenium(II) complex (Δ-Ru1) has great anticancer potential and minor toxicity toward normal tissues. However, the therapeutic efficacy and mechanism of action of ruthenium(II) complex combined with other anticancer drugs is still unknown. Here, we investigated the combinational effect of Δ-Ru1 and doxorubicin in different cancer cells. The data assessed by Chou-Talalay method showed significant synergism in MCF-7 cells. Furthermore, the results in antiproliferation efficacy indicated that the combination showed strong cytotoxicity and increasing apoptosis of MCF-7 cells in 2D and 3D multicellular tumor spheroids (MCTSs). Significant inhibition of MCF-7 cells accompanied with increased ROS generation was observed. Furthermore, the expression of PI3K/AKT was significantly down-regulated, while the expression of PTEN was strongly up-regulated in cells treated with combination of Δ-Ru1 and doxorubicin. The expression of NF-κB and XIAP decreased while the expression of P53 increased and associated with apoptosis. These findings suggest that the combination of ruthenium complex and doxorubicin has a significant synergistic effect by down-regulating the PI3K/AKT signaling pathway in MCF-7 cells. This study may trigger more research in ruthenium complex and combination therapy that will be able to provide opportunities for developing better therapeutics for cancer treatment.

27 November 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
KQKangqiang Qiu
Kangqiang Qiu
JWJinQuan Wang
JinQuan Wang
TRThomas W. Rees
Thomas W. Rees
LJLiangnian Ji
Liangnian Ji
QZQianling Zhang
Qianling Zhang
HCHui Chao
Hui Chao
A mitochondria-targeting photothermogenic nanozyme was used to increase localized temperature and accelerate the catalysis of H2O2 to ˙OH under NIR light irradiation for mild photothermal therapy.

9 September 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
ZZZizhuo Zhao
Zizhuo Zhao
KQKangqiang Qiu
Kangqiang Qiu
JLJiangping Liu
Jiangping Liu
XHXiaojuan Hao
Xiaojuan Hao
JWJinQuan Wang
JinQuan Wang
An RGD-peptide conjugated ruthenium(II) complex has been developed, which functions as a two-photon absorption (TPA) photodynamic therapy (PDT) agent for ablating tumours by selectively targeting the mitochondria of integrin αvβ3-rich tumour cells. This approach offers a new and effective design and application for tumour-targeting metallo-anticancer drugs via two-photon PDT.